dialysis advent access
A man awaits dialysis. (Representational Image) Reuters

Singapore-based medtech company Advent Access has raised S$2.6 million from Temasek to advance the development and commercialisation of its patented av-Guardian technology.

The financing was led by Temasek-backed Accuron MedTech (Accuron), the largest medical device company in South-east Asia.

Advent Access, a company spun off from the Agency for Science, Technology and Research, has developed av-Guardian that allows for easier access to veins and reduces complications from long-term dialysis treatment.

Vascular access is necessary for patients undergoing dialysis, but if the dialysis needles are not well placed, complications can arise.

It is the most common cause of hospitalisation in patients suffering end-stage renal disease, which affects the cost of the treatment and the patient's quality of life.

The company's device helps solve this issue by providing a "guide door" for dialysis needles to enter and access blood from a consistent position, angle and depth.

The funds raised will be used to complete an ongoing clinical trial as well as to advance av-Guardian towards a filing for CE mark certification within the next 18 months - a major milestone in making the device available to patients globally.